News

PMLive1d
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...
Zacks Investment Research on MSN4d
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...
Fierce Biotech1h
Investors sweet on Nektar as phase 2b eczema success doubles share price
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
PMLive12d
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones ...
Wall Street Journal3d
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...